ANDA 89323, held by Abraxis Pharmaceuticals. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 89323 (Methotrexate Sodium), held by Abraxis Pharmaceuticals, was first approved by FDA on Jun 13, 1986, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 13, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 2.5MG BASE/ML · injectable;injection | Methotrexate Sodium | Discontinued |
| Dec 18, 1990 | Supplement 7Labeling | Approved | None posted |
| Feb 17, 1989 | Supplement 4Labeling | Approved | None posted |
| Jun 13, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters